Effect of relapses on development of residual deficit in multiple sclerosis
Top Cited Papers
- 9 December 2003
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 61 (11) , 1528-1532
- https://doi.org/10.1212/01.wnl.0000096175.39831.21
Abstract
Objective: To determine the percentage of patients with residual deficits following multiple sclerosis (MS) exacerbations and the magnitude of those deficits using a database of pooled placebo patients from clinical trials. Methods: A database of patients assigned to the placebo group in several randomized clinical trials was queried to determine those patients with Expanded Disability Status Scale (EDSS) and Scripps Neurologic Rating Scale assessments prior to, at the time of, and after an acute exacerbation of MS. The extent of deficit present at these time points was compared to determine the acute effect of exacerbations and the degree of persistent disability. Results: Forty-two percent of patients had residual deficit of at least 0.5 and 28% had residual of ≥1.0 EDSS units, at an average of 64 days after an exacerbation. The results were reproduced across subsequent exacerbations and were sustained over time. The subgroup of patients with measurable change in EDSS during the exacerbation had more extensive residual impairment on the follow-up visits. Similar results were seen when the Scripps score was examined. Conclusion: MS exacerbations produce a measurable and sustained effect on disability.Keywords
This publication has 14 references indexed in Scilit:
- Relapses and Progression of Disability in Multiple SclerosisNew England Journal of Medicine, 2000
- Multiple SclerosisNew England Journal of Medicine, 2000
- Recommendations from the national multiple sclerosis society clinical outcomes assessment task forceAnnals of Neurology, 1997
- Clinical outcomes assessment in multiple sclerosisAnnals of Neurology, 1996
- Defining the clinical course of multiple sclerosisNeurology, 1996
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993
- A neurologic rating scale (NRS) for use in multiple sclerosisNeurology, 1984
- Rating neurologic impairment in multiple sclerosisNeurology, 1983